<< Back To Search

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

Notify the Multiple Myeloma Research Foundation you are interested in this trial
NCT05645107
Age 18 +
Sex Both
Phase Phase 3
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients. The study focuses on a specific combination of therapies that may improve outcomes for individuals dealing with this condition. Here are some key points about the study:
  • The treatment involves a combination of existing therapies, which may enhance their effectiveness when used together.
  • This study is unique because it looks at how these therapies work in combination, rather than testing them individually.
  • Participants will receive the treatment in a controlled environment, allowing researchers to closely monitor its effects.
  • The study aims to gather data on how well this combination works compared to standard treatments.
  • Researchers are also interested in understanding the side effects and overall safety of the new treatment approach.
Overall, this study represents an important step in finding more effective treatment options for patients, potentially leading to better management of their condition.
Third Opinion AI Generated Synopsis

Trial Summary
The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in B-cell CLL, MM, and NHL participants with hypogammaglobulinemia (HGG) in comparison to the Placebo plus SMT group.
from ClinicalTrials.gov

Locations & Contact

Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: